Evidence map›Paper›PMID 28479727›Full record

ArticlePharmacognosy magazine2017

Exploratory Studies of (-)-Epicatechin, a Bioactive Compound of

Bhasha Shanmugam, Kondeti Ramudu Shanmugam, Sahukari Ravi, Ganjikunta Venkata Subbaiah, Chilakala Ramakrishana, Korivi Mallikarjuna, Kesireddy Sathyavelu Reddy

Abstract read
In one paragraph

Article in Pharmacognosy magazine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Compounds of plants with activity against SARS-CoV-2 targets.Expert review of clinical pharmacology · 2021
    Pooled it
  3. Article
  4. Antioxidants (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Impacts ofNarra J · 2024
    Article
  7. Hepatoprotective Effects of (-) Epicatechin in CClEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bhasha ShanmugamDivision of Molecular Biology and Ethanopharmacology, Department of Zoology, Sri Venkateswara University, Tirupati, India.
Kondeti Ramudu ShanmugamDepartment of Zoology, T.R.R. Government Degree College, Kandukur, Andhra Pradesh, India.
Sahukari RaviDivision of Molecular Biology and Ethanopharmacology, Department of Zoology, Sri Venkateswara University, Tirupati, India.
Ganjikunta Venkata SubbaiahDivision of Molecular Biology and Ethanopharmacology, Department of Zoology, Sri Venkateswara University, Tirupati, India.
Chilakala RamakrishanaMineral Resources Research Division, Korea Institute of Geoscience, Gwahak-ro, Yuseong-gu, Daejeon, South Korea.
Korivi MallikarjunaInstitute of Nutrition (16F), China Medical University, Hsueh-Shih Road, North District, Taichung, Taiwan.
Kesireddy Sathyavelu ReddyDivision of Molecular Biology and Ethanopharmacology, Department of Zoology, Sri Venkateswara University, Tirupati, India.
Sri Venkateswara University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis is a health problem affecting millions of people worldwide and it is the major risk factor for liver cirrhosis. In India, many plants are used to treat hepatitis. But little is known about the effects of (-)-epicatechin a bioactive compound of

objectiveThe present study was designed to explore the antioxidant property of (-)-epicatechin isolated from PN in D-Galactosamine (D-GalN) induced hepatitis rats. MATERIALS AND

methodsThe rats are divided into five groups as per the experimental design. (-)-Epicatchin pretreatment was given to the hepatitis rats for 21 days and biochemical analysis was carried out. The hepatic antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GR), glutathione S-transferase (GST), reduced glutathione (GSH), and malondialdehyde (MDA) and serum markers aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), albumin, and bilirubin are estimated.

resultsAll the antioxidant enzymes activities and albumin levels are depleted in hepatitic rats. Whereas GST, ALP, AST, ALT activities and MDA, and bilirubin levels are elevated in hepatitis rats, (-)-epicatechin pretreatment increased all the antioxidant enzymes and decreased the GST, ALP, AST, ALT, and MDA levels in hepatitis rats. However, histopatholoigic studies also proves that (-)-epicatechin pretreatment decreased the tissue damage in hepatitis condition. This is the first report on the antioxidant enzymes and hepatoprotective effect of (-)-epicatechin in hepatitis rats.

conclusionFrom this study, we conclude that (-)-epicatechin treatment decreased the oxidative damage in hepatitis rats. SUMMARY: The present study was carried out to know the impact of (-)-epicatechin on antioxidant enzymes activities in hepatitis rats. From this study, we found that the antioxidant enzymes SOD, CAT, GPx, GR, GSH depleted in hepatitis rats and increased with (-)-epicatechin in hepatitis rats.MDA levels increased in hepatitis rats and decreased with (-)-epicatechin in hepatitis rats. From this study, we concluded that (-)-epicatechin will be useful to treat hepatotoxicity in rats.

Indexed as

antioxidants enzymes(-)-Epicatechinhepatitisliver markers

Identifiers

PMID28479727
PMCPMC5407117
OpenAlexW2605559124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.